the role of immune checkpoint inhibitors in mds
Published 3 years ago • 92 plays • Length 4:27Download video MP4
Download video MP3
Similar videos
-
5:42
immune checkpoint inhibitors in mds and aml
-
1:59
topics of interest in mds: the role of maintenance therapy, immune checkpoints & ven-aza in hr-mds
-
7:32
current immune checkpoint inhibitor trials in aml/mds
-
4:55
checkpoint inhibitor combination approaches for aml/mds: an update
-
2:53
immune checkpoint inhibitors in mds: the i4mds consortium
-
2:12
allosct for aml with mds-related features as per the icc and who 2022 classifications
-
9:41
the i4mds consortium and immune monitoring in mds
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:25
the recent approval of imetelstat in lr-mds based on results of the imerge trial
-
4:10
the management of prefibrotic myelofibrosis
-
13:39
key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
-
2:02
unmet needs in high-risk mds and future therapeutic strategies
-
2:04
state-of-the-art treatment for hr-mds
-
2:54
pre/post allo-sct checkpoint inhibitors: a double-edged sword
-
1:51
checkpoint inhibition in the treatment of mpns
-
1:26
incidence and risk factors associated with vod/sos in younger vs older adults after sct
-
1:13
challenges in risk stratifying lr-mds: insights into genetic upstaging and early transplant
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
1:53
immuno-oncology paving the way in mds
-
11:33
treatment algorithm for low-risk mds
-
3:17
pre-mds states: novel therapeutic approaches, and determining appropriate trial endpoints